Rosalia I. Russo-Cordo

Vuelta De Obligado, B C1428ADN, Argentina

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.

Correction: Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.

Journal: Cell death & disease

Published: December 15, 2023

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.

Blocking soluble TNFα sensitizes HER2-positive breast cancer to trastuzumab through MUC4 downregulation and subverts immunosuppression.

Journal: Journal for immunotherapy of cancer

Published: February 21, 2023

Proteoglycans: A Tool for Detecting Hyaluronan by ELISA-Like Methods.

Proteoglycans: A Tool for Detecting Hyaluronan by ELISA-Like Methods.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: January 20, 2023

Cancer immune exclusion: breaking the barricade for a successful immunotherapy.

Cancer immune exclusion: breaking the barricade for a successful immunotherapy.

Journal: Frontiers in oncology

Published: December 31, 2022

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.

Halting ErbB-2 isoforms retrograde transport to the nucleus as a new theragnostic approach for triple-negative breast cancer.

Journal: Cell death & disease

Published: February 02, 2022

Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.

Nuclear PDCD4 Expression Defines a Subset of Luminal B-Like Breast Cancers with Good Prognosis.

Journal: Hormones & cancer

Published: February 07, 2020

Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.

Canonical ErbB-2 isoform and ErbB-2 variant c located in the nucleus drive triple negative breast cancer growth.

Journal: Oncogene

Published: December 14, 2019

Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Nuclear ErbB-2: a Novel Therapeutic Target in ErbB-2-Positive Breast Cancer?

Journal: Hormones & cancer

Published: November 07, 2018

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.

Invasive micropapillary carcinoma of the breast overexpresses MUC4 and is associated with poor outcome to adjuvant trastuzumab in HER2-positive breast cancer.

Journal: BMC cancer

Published: June 16, 2017

ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.

ErbB-2 nuclear function in breast cancer growth, metastasis and resistance to therapy.

Journal: Endocrine-related cancer

Published: October 03, 2016

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1.

Journal: Oncogene

Published: December 13, 2015

Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

Heregulin Co-opts PR Transcriptional Action Via Stat3 Role As a Coregulator to Drive Cancer Growth.

Journal: Molecular endocrinology (Baltimore, Md.)

Published: September 05, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026